Drugs / Ceftazidime-avibactam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02504827 | Sep 2015 → Oct 2016 | cystic fibrosis | University of Southern California | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ceftazidime-avibactam | “Ceftazidime-avibactam (CZA) demonstrates excellent in vitro activity against isolates recovered from CF patients, including drug-resistant strains.” PMID 28784670 ↗ Sep 2017 |
| Known as | CZA | “Ceftazidime-avibactam (CZA) demonstrates excellent in vitro activity against isolates recovered from CF patients, including drug-resistant strains.” PMID 28784670 ↗ Sep 2017 |
| Route | Intravenous | “administered 3 intravenous doses of 2.5 g every 8 h infused over 2 h” PMID 28784670 ↗ Sep 2017 |